Docket No. 21545-US1

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Total Pages in this Submission

. PTO

TO THE COMMISSIONER FOR PATENTS

Mail Stop Patent Application P.O. Box 1450 Alexandria, VA 22313-1450

Ų	
Ť	Ö
α.	~
'n	S
~	\approx
\supset	0
	Ŋ
	\sim

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an ∞ invention entitled: MANNITOL AND GLUCITOL DERIVATIVES and invented by: Frank BERGMANN, Herbert VON DER ELTZ, Christop SEIDEL and Kurt WEINDEL If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information: ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: Continuation Which is a: □ Continuation ☐ Continuation-in-part (CIP) of prior application No.: Divisional Which is a: □ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: Enclosed are: **Application Elements** Filing fee as calculated and transmitted as described below 2. \boxtimes Specification having pages and including the following: a. 🛛 Descriptive Title of the Invention b. **⊠** Cross References to Related Applications (if applicable) c. 🗆 Statement Regarding Federally-sponsored Research/Development (if applicable) d. 🗵 Reference to Sequence Listing, a Table, or a Computer Program Listing Appendix e. 🗵 Background of the Invention f. 🗵 Brief Summary of the Invention \boxtimes Brief Description of the Drawings (if filed) h. 🗵 **Detailed Description** i. 🛛 Claim(s) as Classified Below i. 🛛 Abstract of the Disclosure

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 21545-US1

Total Pages in this Submission

Application Elements (Continued)

3.	X	Drawing(s) (when necessary as prescribed by 35 USC 113)						
	a.	□						
	b.	☐ Informal Number of Sheets						
4.	\boxtimes	Oath or Declaration						
	a.	☐ Newly executed (original or copy) ☑ Unexecuted						
	b.	☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)						
	Ċ.	With Power of Attorney Without Power of Attorney						
	d.	☐ <u>DELETION OF INVENTOR(S)</u> Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).						
5.		Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.						
6.		CD ROM or CD-R in duplicate, large table or Computer Program (Appendix)						
7.	\boxtimes	Application Data Sheet (See 37 CFR 1.76)						
8.	\boxtimes	Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)						
	a.							
	b.	☑ Specification Sequence Listing on:						
		i. CD-ROM or CD-R (2 copies); or						
		ii. 🗵 Paper						
	C.	Statement(s) Verifying Identical Paper and Computer Readable Copy						
		Accompanying Application Parts						
9.		Assignment Papers (cover sheet & document(s))						
10.		37 CFR 3.73(B) Statement (when there is an assignee)						
11.		English Translation Document (if applicable)						
12.	X	Information Disclosure Statement/PTO-1449 Copies of IDS Citations						
13.	\boxtimes	Preliminary Amendment						
14.	\boxtimes	Return Receipt Postcard (MPEP 503) (Should be specifically itemized)						
15.	\boxtimes	Certified Copy of Priority Document(s) (if foreign priority is claimed)						
16.	X	Certificate of Mailing						
		☐ First Class ☒ Express Mail (Specify Label No.): EV 338302940US						

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 21545-US1

Total Pages in this Submission

Accompanying Application Parts (Continued)

17.	X	Additional Enclosures (please identify below):				
		Certified copies of priority European Patent Application Nos. 02028714.0 filed December 20, 2002 and and 03001215.7 filed January 20, 2003				
		Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)				
18.		Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.				

Warning

An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

Docket No. 21545-US1

1671

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Total Pages in this Submission

U.S. PTO

CC: Customer No. 22829

Fee Calculation and Transmittal

		CLAIMS	AS FILED			
For	#Filed	#Allowed	#Extra		Rate	Fee
Total Claims	31	- 20 =	11	x	\$18.00	\$198.00
Indep. Claims	5	- 3 =	2	×	\$86.00	\$172.00
Multiple Dependent	Claims (check	(if applicable)				\$0.00
					BASIC FEE	\$770.00
OTHER FEE (speci	fy purpose)	-				\$0.00
					TOTAL FILING FEE	\$1,140.00
as described bel Charge to Credit at Charge to Charge t	ereby authorize ow. the amount of ny overpaymen any additional f	\$1,140.00 t. iling fees required et in 37 C.F.R. 1.1	as filing fee. I under 37 C.F	Account I	No. 50-0812	
Dated: Dec. 4, 200	<i>3</i>			harles M.	Doyle, Reg. No. 39,175	

Page 4 of 4

ROCHE MOLECULAR SYSTEMS, INC.

Patent Department 1145 Atlantic Avenue

Alameda, California 94501

CERTIFICATE OF N Applicant(s): Frank Berg	MAILING BY "EXPRESS I gman,et al.	MAIL" (37 CFR 1.10)	Docket No.					
			21545-US1					
Serial No.	Filing Date Even date herewith	Examiner Unassigned	Group Art Unit Unassigned					
Invention:	MANNITOL AND GLUCITO	L DERIVATIVES						
I hereby certify that the following correspondence: Utility Patent Application Transmittal Letter, Preliminary Amendment, Unsigned Declaration and Power of Attorney, Specification 43pp, Claims 9pp, Abstract 1 p & 4 sheets of Drawing, IDS and 48 References, SeqListing Statement under 1.821, 2pp Seq Listing and Diskette; Application Data sheet, Certified copies of EP02028714.0 and 03001215.7, Express Mailing Label EV338302940US and Return receipt Postcard (Identify type of correspondence) is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on Winsome Punn (Typed or Printle Name of Person Mailing Correspondence) (Signature of Person Mailing Correspondence) EV338302940US								
		("Express Mail" Mailing Lab	el Number)					

Note: Each paper must have its own certificate of mailing.